EFFICACY AND SAFETY OF SWITCHING FROM ETANERCEPT REFERENCE PRODUCT TO LBEC0101 (ETANERCEPT BIOSIMILAR) COMPARED WITH CONTINUING LBEC0101 IN PATIENTS WITH RHEUMATOID ARTHRITIS

被引：3
|
作者：
Song, Y. W. [1 ]
Matsuno, H. [2 ,3 ]
Park, M. -C. [4 ]
Tomomitsu, M. [5 ]
Shin, S. [6 ]
Lee, J. [6 ]
机构：
[1] Seoul Natl Univ Hosp, Seoul, South Korea
[2] Tokyo Med Univ, Tokyo, Japan
[3] Matsuno Clin Rheumat Dis, Toyama, Japan
[4] Yonsei Univ, Div Rheumatol, Coll Med, Seoul, South Korea
[5] Mochida Pharmaceut Co Ltd, Tokyo, Japan
[6] LG CHEM, Seoul, South Korea
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2018年 / 77卷
关键词：
D O I：
10.1136/annrheumdis-2018-eular.1316
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
AB0456
引用
收藏
页码：1389 / 1390
页数：3
相关论文
共 50 条
  • [21] Costs associated with non-medical switching from originator to biosimilar etanercept in patients with rheumatoid arthritis in the UK
    Tarallo, Miriam
    Onishchenko, Kateryna
    Alexopoulos, Stamatia T.
    JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (11) : 1162 - 1170
  • [22] Costs Associated with Non-Medical Switching from Originator to Biosimilar Etanercept in Patients with Rheumatoid Arthritis in the UK
    Onishchenko, Kateryna
    Alexopoulos, Stamatia Theodora
    Curiale, Cinzia
    Tarallo, Miriam
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [23] Efficacy of etanercept biosimilar switching from etanercept reference product, using ultrasound and clinical data in outcomes of real world therapy (ESCORT-NGSK Study)
    Sumiyoshi, Remi
    Kawashiri, Shin-ya
    Shimizu, Toshimasa
    Koga, Tomohiro
    Kiya, Rieko
    Tashiro, Shigeki
    Kawazoe, Yurika
    Sato, Shuntaro
    Ueki, Yukitaka
    Suzuki, Takahisa
    Tsuboi, Masahiko
    Tada, Yoshifumi
    Hidaka, Toshihiko
    Takaoka, Hirokazu
    Hosogaya, Naoki
    Yamamoto, Hiroshi
    Kawakami, Atsushi
    DRUG DISCOVERIES AND THERAPEUTICS, 2025,
  • [24] Etanercept Biosimilar GP2015 Has Equivalent Efficacy and Safety to Etanercept Originator in Patients with Moderate to Severe Rheumatoid Arthritis: The Phase 3 Equira Study
    Kavanaugh, Arthur
    Allanore, Yannick
    Kucharz, Eugeniusz J.
    Babic, Goran
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [25] A COMPARATIVE STUDY TO ASSESS THE EFFICACY, SAFETY, AND IMMUNOGENICITY OF YLB113 AND ETANERCEPT REFERENCE PRODUCT FOR THE TREATMENT OF PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS
    Yamanaka, Hisashi
    Kamatani, Naoyuki
    Tanaka, Yoshiya
    Hibino, Toshihiko
    Drescher, Edit
    Sanchez-Burson, Juan
    Rettenbacher, Manfred
    Bhatia, Girish
    Gadve, Snehal
    Shah, Chirag
    Bakhle, Dhananjay
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 1670 - 1670
  • [26] Comparison of injection-site reactions between the etanercept biosimilar SB4 and the reference etanercept in patients with rheumatoid arthritis from a phase III study
    Girolomoni, G.
    Feldman, S. R.
    Emery, P.
    Ghil, J.
    Keum, J. W.
    Cheong, S. Y.
    Hong, E.
    BRITISH JOURNAL OF DERMATOLOGY, 2018, 178 (03) : E215 - E216
  • [27] Comparison between Continuing SB4 (Etanercept Biosimilar) and Switching from Reference Etanercept to SB4: Long-Term Safety and Efficacy of SB4 from a Phase III Study
    Emery, Paul
    Vencovsky, Jiri
    Sylwestrzak, Anna
    Leszczynski, Piotr
    Porawska, Wieslawa
    Stasiuk, Barbara
    Hilt, Joanna
    Mosterova, Zdenka
    Cheong, Soo-Yeon
    Ghil, Jeehoon
    JOURNAL OF RHEUMATOLOGY, 2017, 44 (06) : 877 - 878
  • [28] COST EFFECTIVENESS OF A HIGH INTENSITY PROGRAMME (HIP) COMPARED TO A LOW INTENSITY PROGRAMME (LIP) FOR SWITCHING PATIENTS WITH RHEUMATOID ARTHRITIS TO THE ETANERCEPT BIOSIMILAR
    Shah, Kavina
    Flora, Kalveer
    Penn, Henry
    RHEUMATOLOGY, 2018, 57
  • [29] Efficacy, safety and immunogenicity of GP2015, an etanercept biosimilar, compared with the reference etanercept in patients with moderate-to-severe rheumatoid arthritis: 24-week results from the comparative phase III, randomised, double-blind EQUIRA study
    Matucci-Cerinic, Marco
    Allanore, Yannick
    Kavanaugh, Arthur
    Buch, Maya H.
    Schulze-Koops, Hendrik
    Kucharz, Eugeniusz J.
    Woehling, Heike
    Babic, Goran
    Poetzl, Johann
    Davis, Adanna
    Schwebig, Arnd
    RMD OPEN, 2018, 4 (02):
  • [30] Efficacy, safety and immunogenicity of etanercept biosimilars versus reference biologics in patients with rheumatoid arthritis: A meta-analysis
    Hu, Rui
    Yuan, Tao
    Wang, Hui
    Zhao, Jianglin
    Shi, Liya
    Li, Quankai
    Zhu, Chunmei
    Su, Na
    Zhang, Shengzhao
    FRONTIERS IN PHARMACOLOGY, 2023, 14
12345